Background {#Sec1}
==========

Acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) is characterized by abnormal pulmonary physiology and gas exchange properties \[[@CR1], [@CR2]\], which are common complications in various diseases, and is related to higher morbidity and mortality \[[@CR3], [@CR4]\]. Generally, the process of gas exchange is completed by mechanical ventilation. However, mechanical ventilation does not significantly reduce the mortality caused by ALI/ARDS. Rather, the lung injury could aggravated by ventilator due to surfactant deficiency and dysfunction, which associated with the exacerbation of atelectasis, increased formation of oedema, and impairment of local host defence \[[@CR4]--[@CR7]\]. Until now, the effect of most-employed treatment strategies, including high dose of steroids, aspirin, and ulinastain, in patients with ALI/ARDS remains limited \[[@CR8]\].

Sivelestat is a neutrophil elastase inhibitor, which induces competitive inhibition of neutrophils, inhibition of neutrophil activation, and reduction of inflammation in the lungs \[[@CR9], [@CR10]\]. Currently, the use of sivelestatis already approved in Japan \[[@CR11], [@CR12]\]. However, the effectiveness of sivelestat in clinical needs is yet to be interpreted. Several randomized controlled trials (RCTs) have indicated that sivelestat therapy can improve ventilation days and arterial oxygen partial pressure (PaO2)/fractional inspired oxygen (FiO2), while the efficacy of sivelestat therapy on other outcomes in patients with ALI/ARDS remains controversial. Therefore, a systematic review and meta-analysis of available RCTs were conducted to evaluate the treatment effect of sivelestat.

Methods {#Sec2}
=======

Data sources, search strategy, and selection criteria {#Sec3}
-----------------------------------------------------

This review was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis Statement issued in 2009 (Additional file [1](#MOESM1){ref-type="media"}: Checklist S1) \[[@CR13]\].

A systematic review and meta-analysis of RCTs published through April 2017 were conducted to identify trials of sivelestat for patients with ALI/ARDS. Electronic databases PubMed, Embase, and the Cochrane Library were searched using the following key words: ("sivelestat" OR "elaspol") AND ("ARDS" OR "adult respiratory distress syndrome" OR "acute respiratory distress syndrome" OR "noncardiogenic pulmonary edema" OR "respiratory insufficiency" OR "systemic inflammatory response syndrome" OR "shock lung" OR "respiratory failure" OR "lung injury\*" OR "septic shock" OR "sepsis"). Manual searches of the reference lists were also conducted from all relevant original and review articles to identify additional eligible studies. No language restriction was applied. Unpublished trials were excluded. The medical subject heading, methods, patient disease status, study design, intervention, and outcome variables were used to identify relevant studies.

The literature search was independently performed by two authors using a standardized approach. Any inconsistencies were settled by a group discussion until a consensus was reached. The included studies met the following criteria. (1) RCTs, (2) patients confirmed with ALI/ARDS, (3) patients received sivelestat, and (4) data included 28--30 days mortality, improved ventilation days, PaO~2~/FiO~2~ level, and intensive care unit (ICU) stays. All retrospective clinical studies that could affect the treatment effects due to various confounding biases were excluded.

The ethical approval and written consent are not necessary for the meta-analysis, because the data of meta-analysis is collected from published literature.

Data collection and quality assessment {#Sec4}
--------------------------------------

The data collected included the first author's name, publication year, country, sample size, mean age, percentage of male, disease status, intervention, baseline PaO~2~/FiO~2~ ratio, baseline acute physiology and chronic health evaluation (APACHE II) score, reported endpoints, and study design variables. The authors independently scanned the titles and abstracts of the studies for eligibility and relevance. Potentially relevant articles were retrieved and reviewed for selection based on the inclusion and exclusion criteria. Any discrepancies were resolved by discussion. Further, the Jadad scale was employed to evaluate the methodological quality, based on randomization, concealment of treatment allocation, blinding, completeness of follow-up, and use of intention-to-treat analysis \[[@CR14]\].

Statistical analysis {#Sec5}
--------------------

Relative risks (RRs) and standard mean differences (SMDs) with 95% confidence intervals (CIs) were calculated using outcomes extracted from each study before data pooling. The random-effects model was used to calculate pooled RRs with 95% CI to estimate the effect of sivelestat on the risk of 28--30 days mortality, and SMDs were employed to estimate the efficacy of sivelestat therapy on the ventilation days, PaO~2~/FiO~2~ level, and ICU stays \[[@CR15], [@CR16]\]. Heterogeneity among trials was investigated using the Q statistic, and *P* values \<0.10 were indicative of significant heterogeneity \[[@CR17], [@CR18]\]. Sensitivity analyses were conducted for ventilation days and PaO~2~/FiO~2~ level by removing each individual study from the meta-analysis \[[@CR19]\]. The subgroup analysis was also performed for 28--30 days mortality based on publication year, mean age, percentage of male, disease status, baseline PaO~2~/FiO~2~ ratio, and Jadad score. The visual inspection of funnel plots for 28--30 days mortality was conducted. The Egger \[[@CR20]\] and Begg \[[@CR21]\] tests were also used to statistically assess the publication bias for 28--30 days mortality. All reported *P* values were two sided, and *P* values \<0.05 were considered as statistically significant. Statistical analyses were performed using the STATA software (version 10.0; Stata Corporation, TX, USA).

Results {#Sec6}
=======

The results of the study-selection process are shown in Fig. [1](#Fig1){ref-type="fig"}. A total of 541 potentially relevant articles were identified after systematically searching electronic databases, professional journals, and other sources. After reviewing the titles or abstracts, 527 were excluded as they did not meet the inclusion criteria, leaving 14 articles for further full-text reviews. Six RCTs were finally identified and included for the analysis of treatment effect of sivelestat in patients with ALI/ARDS \[[@CR22]--[@CR27]\], and the rest were excluded for the following reasons: conference abstracts without full text, retrospective study, and no desirable outcomes. A manual search of the reference lists of these trials did not yield any new eligible studies. The general characteristics of the included studies are presented in Table [1](#Tab1){ref-type="table"}.Fig. 1Flow diagram of the literature search and trials selection process Table 1Baseline characteristic of studies included in the systematic review and meta-analysisStudyPublication yearCountrySample sizeMean agePercentage male (%)Disease statusInterventionBaseline PaO~2~/FiO~2~ ratioBaseline APACHE II scoreJadad scaleEndo \[[@CR22]\]2006Japan26NANAALI0.2 mg/kg/h for 14 daysNANA3Sato \[[@CR23]\]2008Japan2469.075.0ALI/ARDS0.2 mg/kg/h for 14 days196.5NA2Morimoto \[[@CR24]\]2011Japan2273.163.6ALI0.2 mg/kg/h huntil weaning from mechanical ventilation\<150.0NA3Kadoi \[[@CR25]\]2004Japan2464.075.0ARDS0.2 mg/kg/h for 14 days148.520.12Zeiher \[[@CR26]\]2004Multiple countries48756.059.3ALI0.16 mg/kg/h for 14 days148.720.83Tamakuma \[[@CR27]\]2004Japan22157.876.0ALI0.2 mg/kg/h for 14 days199.0NA3*ALI* Acute lung injury, *APACHE II* acute physiology and chronic health evaluation, *ARDS* acute respiratory distress syndrome, *FiO* ~*2*~ fractional inspired oxygen, *PaO* ~*2*~ arterial oxygen partial pressure

Six RCTs involving a total of 804 patients with ALI/ARDS were included. The mean age of the patients was 56.0--73.1 years. Each trial included 22--487 individuals. Further, the percentage of included males ranged from 59.3%--76.0%. Five trials were conducted in Japan \[[@CR22]--[@CR25], [@CR27]\], and the remaining one trial in multiple countries \[[@CR26]\]. Four of the included trials reported patients with ALI \[[@CR22], [@CR24], [@CR26], [@CR27]\], one trial included patients with ARDS \[[@CR25]\], and the remaining one trial included patients with both ALI and ARDS \[[@CR23]\]. Moreover, five trials included patients who received 0.2 mg/kg/h sivelestat \[[@CR22]--[@CR25], [@CR27]\], and one trial included those who received 0.16 mg/kg/h sivelestat \[[@CR26]\]. The study quality was assessed using the Jadad score and is presented in Table [1](#Tab1){ref-type="table"}. Overall, four trials had a score of 3 \[[@CR22], [@CR24], [@CR26], [@CR27]\], and the remaining two had a score of 2 \[[@CR23], [@CR25]\].

All included trials reported the effect of sivelestat on the risk of 28--30 days mortality. The summary results indicated no significant difference between sivelestat and control for the risk of 28--30 days mortality (RR: 0.94; 95% CI: 0.71--1.23; *P* = 0.643; Fig. [2](#Fig2){ref-type="fig"}), and without evidence of heterogeneity. The sensitivity analysis found that the risk of 28--30 days mortality was reduced by 42%, but was not statistically significant when excluding the study by Zeiher et al. (RR: 0.58; 95% CI: 0.29--1.18; *P* = 0.131; Fig. [2](#Fig2){ref-type="fig"}). This trial specifically included a higher incidence of mortality within 28--30 days and included patients who received low-dose sivelestat therapy.Fig. 2Effect of sivelestat on the risk of 28--30 days mortality

A total of five trials reported the effect of sivelestat therapy on ventilation days in patients with ALI/ARDS. No significant difference was found between sivelestat and control for ventilation days (SMD: 0.05; 95% CI: −0.27 to 0.38; *P* = 0.748; Fig. [3](#Fig3){ref-type="fig"}). Although substantial heterogeneity was observed in the magnitude of the effect across the studies (*P* = 0.028), the conclusion was not affected by the exclusion of any specific study after the sequential exclusion of each study from all of the pooled analyses (Table [2](#Tab2){ref-type="table"}).Fig. 3Effect of sivelestat therapy on ventilation days Table 2Sensitivity analysis for ventilation days and PaO~2~/FiO~2~OutcomesExcluding studySMD (95% CI)*P* valueHeterogeneity (%)*P* value for heterogeneityVentilation daysSato−0.02 (−0.29 to 0.25)0.86550.70.107Morimoto0.09 (−0.27 to 0.45)0.63371.40.015Kadoi0.14 (−0.17 to 0.45)0.38861.30.052Zeiher0.08 (−0.48 to 0.64)0.76665.40.034Tamakuma−0.02 (−0.54 to 0.50)0.95062.90.044PaO~2~/FiO~2~Morimoto0.37 (−0.73 to 1.47)0.50797.4\<0.001Kadoi0.53 (−0.58 to 1.64)0.35097.4\<0.001Zeiher0.18 (−0.53 to 0.89)0.62373.20.024Tamakuma0.87 (0.39 to 1.35)\<0.00149.10.140*CI* confidence interval, *FiO* ~*2*~ fractional inspired oxygen, *PaO* ~*2*~ arterial oxygen partial pressure, *SMD* standard mean difference, *RR* relative risk

A total of four trials reported the effect of sivelestat therapy on PaO~2~/FiO~2~ in patients with ALI/ARDS. It was noted that the PaO~2~/FiO~2~ level in patients with ALI/ARDS who received sivelestat therapy had increased by 0.48, although it was not statistically significant (SMD: 0.48; 95% CI: −0.45 to 1.41; *P* = 0.315; Fig. [4](#Fig4){ref-type="fig"}), and the potential evidence of significant heterogeneity was detected (*P* \< 0.001). According to the sensitivity analysis, the study by Tamakuma et al. was excluded because it specifically included patients with higher baseline PaO~2~/FiO~2~ level and might affect the treatment effect of sivelestat therapy. After this exclusion, it was concluded that sivelestat therapy significantly increased the level of PaO~2~/FiO~2~ in patients with ALI/ARDS (SMD: 0.87; 95% CI: 0.39 to 1.35; *P* \< 0.001; Table [2](#Tab2){ref-type="table"}). Moreover, sivelestat therapy had little or no effect on ICU stays in patients with ALI/ARDS (SMD: −9.87; 95% CI: −24.30 to 4.56; *P* = 0.180; Fig. [5](#Fig5){ref-type="fig"}) (Table [3](#Tab3){ref-type="table"}).Fig. 4Effect of sivelestat therapy on PaO~2~/FiO~2~ Fig. 5Effect of sivelestat therapy on ICU stays Table 3Subgroup analyses for 28--30 days mortality excluding the study conducted by Zeiher et al.GroupRR (95% CI)*P* valueHeterogeneity (%)*P* value for heterogeneity*P* value for interaction testPublication year 2005 or after0.49 (0.16--1.52)0.2150.00.9920.696 Before 20050.65 (0.27--1.59)0.3440.00.427Mean age (years)  ≥ 65.00.53 (0.09--2.92)0.4620.00.9490.897  \< 65.00.60 (0.28--1.28)0.1860.00.677Percentage male (%)  ≥ 70.00.63 (0.27--1.44)0.2720.00.7130.741  \< 70.00.48 (0.13--1.79)0.2770.00.898Disease status ALI0.48 (0.20--1.15)0.1000.00.9920.468 ALI/ARDS or ARDS0.83 (0.25--2.71)0.7570.00.611Baseline PaO~2~/FiO~2~ ratio  ≥ 1500.48 (0.17--1.37)0.1700.00.9750.634  \< 1500.68 (0.26--1.77)0.4300.00.751Jadad score 30.48 (0.20--1.15)0.1000.00.9920.468 20.83 (0.25--2.71)0.7570.00.611*ALI* Acute lung injury, *ARDS* acute respiratory distress syndrome, *CI* confidence interval, *FiO* ~*2*~ fractional inspired oxygen, *PaO* ~*2*~ arterial oxygen partial pressure, *RR* relative risk

The publication bias was assessed using the funnel plot for 28--30 days mortality (Fig. [6](#Fig6){ref-type="fig"}). Although the Begg test showed no evidence of publication bias for 28--30 days mortality, the Egger test showed potential evidence of publication bias. However, the results were not influenced after adjustment for publication bias using the trim-and-fill method \[[@CR28]\].Fig. 6Funnel plot for 28--30 days mortality

Discussion {#Sec7}
==========

The objective of the present meta-analysis was to evaluate the effect of sivelestat therapy in patients with ALI/ARDS. Six trials including 804 patients with ALI/ARDS were included. The summary results showed that sivelestat therapy had little or no significant effect on 28--30 days mortality, ventilation days, PaO~2~/FiO~2~ level, and ICU stays. The findings of the sensitivity analysis indicated that sivelestat therapy might play a beneficial effect on the level of PaO~2~/FiO~2~. These results might help better define the treatment effect of sivelestat therapy in patients with ALI/ARDS and help physicians to select appropriate treatment strategies.

A previous meta-analysis including eight trials suggested that sivelestat therapy was not associated with 28--30 days mortality and mechanical ventilation days, while it was associated with lower PaO~2~/FiO~2~ ratio in patients with ALI/ARDS \[[@CR29]\]. The study did not recommend its routine use in patients with ALI/ARDS. The effect of sivelestat therapy on ICU stays was not conducted, and the treatment effects according to different baseline characteristics were not performed. Therefore, the present study conducted a comprehensive systematic review and meta-analysis to evaluate the effect of sivelestat therapy in patients with ALI/ARDS.

The findings of the present study suggested that sivelestat therapy had no significant effect on 28--30 days mortality. All included trials reported that sivelestat therapy did not affect the risk of mortality within 28--30 days. However, nearly all trials reported that the incidence of 28--30 days mortality reduced but was not statistically significant. Moreover, Zeiher et al. found that sivelestat therapy was associated with a nonsignificant increase in the risk of 28 days mortality by 2% \[[@CR26]\]. The possible reason could be the efficacy of sivelestat on 28 days mortality which might be affected by specific clinical conditions \[[@CR30]\]. Meanwhile, sivelestat has maximum efficacy in patients with mild to moderate ARDS \[[@CR31]\]. Further, the treatment effects of sivelestat were correlated with age, disease status, haemodialysis, and methylprednisoline use \[[@CR32]\]. Furthermore, subgroup analyses for 28 days mortality, excluding the study conducted by Zeiher et al., were performed \[[@CR26]\]. The findings of subgroup analysis were consistent with the overall analysis.

No significant difference was found between sivelestat therapy and control for ventilation days. Mostly included trials indicated that sivelestat therapy had no significant effect on ventilation days, while the trial conducted by Sato et al. reported inconsistent results \[[@CR23]\]. This study specifically included patients with both ALI and ARDS, which might affect ventilation days. Further, the Sato's study might include more severe ALI/ARDS patients, which was associated with lower respiratory function so that sivelestat became less effective \[[@CR33]\]. Finally, sivelestat therapy did not affect the PaO~2~/FiO~2~ level, and ICU stays in ALI/ARDS patients. However, these conclusions may be variable since a smaller number of trials were included. Therefore, the present study gave a relative result and provided a synthetic and comprehensive review.

The strengths of this meta-analysis were as follows: (1) the large sample size allowed the quantitative assessment of the efficacy of sivelestat, and thus these findings were potentially more robust than any individual study. Second, the results of ICU stays were summarized, as the previous meta-analysis was not conducted. Third, the treatment effect of sivelestat in patients with ALI/ARDS according to different baseline characteristics was conducted, which provided any potential effect of sivelestat therapy in specific subpopulations.

The limitation of this study were as follows: (1) the number of included studies was smaller than expected, which always acquired broad CIs, that is, no statistically significant difference; (2) data on baseline APACHE score of the enrolled patients were available in two trials, which might affect the treatment effect of sivelestat in ALI/ARDS patients \[[@CR25], [@CR26]\]; (3) the information about ALI/ARDS classification were available in two trials \[[@CR26], [@CR27]\] and other trials could not provide diagnosis criteria of ALI/ARDS patients, which was correlated with the treatment effects of sivelestat; (4) mostly included trials were conducted in Japan, which might induce ethnic biases; (5) in a meta-analysis of published studies, publication bias is inevitable; and (6) the analysis used pooled data (individual data were not available), which prevented a detailed analysis to obtain more comprehensive results.

Conclusion {#Sec8}
==========

The findings of this study suggested that sivelestat therapy might play an important role on the PaO~2~/FiO~2~ level, while it had no significant effect on 28--30 days mortality, ventilation days, and ICU stays. Future large-scale trials should focus on different disease status, patient characteristics, and trials from other countries to analyze any possible efficacy and safety of sivelestat therapy.
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ALI

:   Acute lung injury

ARDS

:   Acute respiratory distress syndrome

CIs

:   Confidence intervals

FiO2

:   Fractional inspired oxygen

ICU

:   Intensive care unit

PaO2

:   Arterial oxygen partial pressure

RCTs

:   Randomized controlled trials

RR

:   Relative risk

SMD

:   Standard mean difference
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